Li Wei, Liu Ke-Jia, Song Jing-Song, Song Rui, Liu Zi-Liang
Department of Oncology, The First Peoples Hospital of Tianmen City Tianmen 431700, Hubei Province, China.
Department of Cardiothoracic Surgery, The First Peoples Hospital of Tianmen City Tianmen 431700, Hubei Province, China.
Int J Clin Exp Med. 2015 Feb 15;8(2):2326-33. eCollection 2015.
RAD51 interacting with BRCA1 and BRCA2 could modulate the penetrance of BRCA1/BRCA2 mutations, which may increase susceptibility for breast cancer by inhibiting DNA repair and genome stability. The purpose of this study was to provide refined statistical evidence for the association between RAD51 polymorphism and breast cancer risk.
We conducted a meta-analysis of 15 publications with a total of 11,766 cancer cases and 11,227 controls. We summarized the data on the association of RAD51 polymorphism with breast cancer risk and performed subgroup analyses by ethnicity and control source. The pooled ORs based on fixed-effects model did not indicate a modified risk of breast cancer associated with RAD51 polymorphism in the overall population. Nor did we find a significant association in any stratified analysis.
This meta-analysis suggested that RAD51 polymorphism did not appear to represent a significant risk factor for breast cancer.
RAD51与BRCA1和BRCA2相互作用可调节BRCA1/BRCA2突变的外显率，这可能通过抑制DNA修复和基因组稳定性增加患乳腺癌的易感性。本研究的目的是为RAD51基因多态性与乳腺癌风险之间的关联提供更精确的统计学证据。
我们对15篇文献进行了荟萃分析，共纳入11766例癌症病例和11227例对照。我们总结了RAD51基因多态性与乳腺癌风险关联的数据，并按种族和对照来源进行了亚组分析。基于固定效应模型的合并比值比未表明RAD51基因多态性与总体人群中乳腺癌风险的改变有关。我们在任何分层分析中也未发现显著关联。
这项荟萃分析表明，RAD51基因多态性似乎不是乳腺癌的显著危险因素。
